CTOs on the Move

Medingo Medical Solutions

www.medingo.com

 
Medingo Medical Solutions is a Valley Lee, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medingo.com
  • Yoqnueam Industrial Park
    Valley Lee, MD USA 20692
  • Phone: 273.713.1305

Executives

Name Title Contact Details

Similar Companies

AART

AART is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Midwest Group

Midwest Group is a Glen Ellyn, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dialyze Direct

Dialyze Direct provides staff assisted home hemodialysis services to elderly patients with End Stage Renal Disease who reside in Nursing Homes. Our mission is to deliver innovative and compassionate dialysis care to geriatric patients in Skilled Nursing Facilities, enhancing their quality of life while significantly reducing overall costs by improving outcomes, eliminating transportation and minimizing re-hospitalizations. The Dialyze Direct program permits an unprecedented degree of on-site coordination of care and sharing information with the nursing home staff, with respect to ESRD care, that include nursing, dietary and social work collaboration. Dialyze Direct has re-purposed home dialysis technology, with enhanced and proprietary protocols that are better suited to the special needs of geriatric patients with multiple co-morbid conditions resulting in improved outcomes, shortened recovery times, increased rehab score gains and decreased re-hospitalizations.

Mim Corporation

Mim Corporation is a Elmsford, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reva Medical

Founded in 1998, REVA Medical is dedicated to developing minimally invasive medical devices that leverage its proprietary biomaterial and stent technologies to improve the treatment of coronary artery disease. Guided by an executive management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA’s initial focus is the development of a drug-eluting bioresorbable coronary scaffold to advance the treatment of cardiovascular disease, the leading cause of death worldwide.